 The FDA has approved Paratek Pharmaceuticals Incs NASDAQ: PRTK supplemental marketing application for the oral-only dosing regimen of Nuzyra for Community-Acquired Bacterial Pneumonia CABP. The approval of an oral-only dose regimen for NUZYRA represents a significant opportunity to treat patients in either the outpatient or primary care setting to potentially reduceseliminates hospitalizations and the associated risk and costs from a hospital stay, the company said. 